Gale, Robert Peter
Robert Peter Gale American medical researcher
Gale, Robert Peter, 1945-....
Gale, Robert Peter, arts, 1945-
VIAF ID: 25910694 (Personal)
Permalink: http://viaf.org/viaf/25910694
Preferred Forms
-
-
-
-
100 1 _ ‡a Gale, Robert Peter
-
100 1 _ ‡a Gale, Robert Peter
-
-
-
-
-
-
100 1 _ ‡a Gale, Robert Peter
-
-
-
100 1 _ ‡a Gale, Robert Peter ‡d 1945-
-
-
100 1 _ ‡a Gale, Robert Peter, ‡d 1945-
-
-
100 1 _ ‡a Gale, Robert Peter, ‡d 1945-....
-
100 0 _ ‡a Robert Peter Gale ‡c American medical researcher
4xx's: Alternate Name Forms (19)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Acute myelogenous leukemia : progress and controversies : proceedings of a Wyeth-Ayerst-UCLA Symposia Western Workshop held at Lake Lanier, Georgia, November 28-December 1, 1989 |
![]() ![]() ![]() |
Advances and controversies in thalassemia therapy : bone marrow transplantation and other approaches : proc. of an intern. symposium..., Urbino, It., sept. 22-25, 1988 |
![]() |
Arts in Moskou : de strijd van een Amerikaanse beenmergchirurg en zijn Russische collega's tegen de gevolgen van Tsjernobyl |
![]() |
Blood stem cell transplants |
![]() ![]() ![]() ![]() ![]() ![]() |
Bone marrow transplantation : current controversies : proceedings of a Sandoz-UCLA Symposium, held at Tamarron, Colorado, March 6-12, 1988 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Chernobyl : the final warning / Robert Peter Gale and Thomas Hauser. - London, 1988. |
![]() ![]() ![]() ![]() ![]() ![]() |
Chronic lymphocytic leukemia : recent progress, future direction : proceedings of a Hyland Laboratories-UCLA symposium held in Napa, California, December 2-5, 1986 |
![]() ![]() ![]() |
Fetal liver transplantation : current concepts and future directions : proceedings of the First International Symposium on Fetal Liver Transplantation, Pesaro, Italy, September, 1979 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Fifth Biennial Sandoz-Keystone Symposium on BMT |
![]() |
Hoshasen to reisei ni mukiaitai minasan e : Sekaiteki ken'i no tokubetsu kogi. |
![]() |
Intl. Symp. on Cell. Immun. of Cancer (1986 : Racine, Wis.). Cellular immunotherapy of cancer, 1987: |
![]() ![]() ![]() |
Keystone symposia workshop: Curing leukemia : proceedings from a symposium held Nov. 26-28, 1990, in Martha's Vineyard, Mass. |
![]() |
Leukemia management, c1986: |
![]() ![]() ![]() |
Leukemia : progress and controversies : Keystone Symposium on Molecular and Cellular Biology, 6-12 April, 1991, Big Sky, Montana, USA |
![]() ![]() |
Leukemia therapy |
![]() ![]() ![]() |
Modeling minimal residual disease |
![]() |
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia |
![]() |
n80112034 |
![]() |
New cancer therapies. Are haematopoietic cell transplants a dead duck? |
![]() |
New study-designs to address the clinical complexity of acute myeloid leukemia |
![]() |
Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT |
![]() |
Nuclear terrorism |
![]() |
Older patients with myeloma derive similar benefit from autologous transplantation. |
![]() |
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors |
![]() |
Paul Ichiro Terasaki September 10, 1929 to January 25, 2016: Transplant Pioneer. |
![]() |
Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia? |
![]() |
Posljednja opomena : nasljeđe Černobilja |
![]() |
Prof. Thomas Büchner (22 September 1934-5 August 2016). A career devoted to research in acute myeloid leukaemia. |
![]() |
Professor John M. Goldman, CML pioneer 1938-2013. |
![]() |
Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia |
![]() |
Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia |
![]() |
A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed POEMS syndrome. |
![]() |
Radiation : what it is, what you need to know |
![]() ![]() ![]() |
Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukaemia |
![]() |
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia |
![]() |
A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. |
![]() |
Recent advances in leukemia and lymphoma : proceedings of a Schering Corporation-UCLA Symposium held in Keystone, Colorado, January 25-31, 1987 |
![]() ![]() ![]() |
Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions |
![]() |
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. |
![]() |
Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups |
![]() |
Statistical analyses of clinical trials in haematopoietic cell transplantation or why there is a strong correlation between people drowning after falling out of a fishing boat and marriage rate in Kentucky |
![]() |
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. |
![]() |
Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia |
![]() |
TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes |
![]() |
TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia |
![]() |
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. |
![]() |
Therapy of posttransplant poor graft function with eltrombopag |
![]() |
Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors. |
![]() |
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma |
![]() |
El Último aviso : el legado de Chernobyl |
![]() |
Unique features of primary myelofibrosis in Chinese |
![]() |
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma |
![]() |
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. |
![]() |
Using routinely gathered data to evaluate locally led service improvements |
![]() |
Why is there so much therapy-related AML and MDS and so little therapy-related CML? |
![]() |
Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia |
![]() |
チェルノブイリ : アメリカ人医師の体験 |
![]() ![]() |
放射線と冷静に向き合いたいみなさんへ : 世界的権威の特別講義 |
![]() ![]() |